Medications for BED (lisdexamfetamine) and T2DM (GLP-1 agonists and SGLT-2 inhibitors) may be useful for supporting treatment goals for both conditions. This evidence concerns the gene GCG and X-linked cone dysfunction syndrome with myopia.